Lupin releases Q4FY22 results
Basis the long-term outlook, the company's Board has recommended a dividend of 200 per cent
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
ICICI Securities
Suven Pharmaceuticals financial results – strong show in FY20; outlook upbeat: ICICI…
Net profit for FY20 was at Rs 317 crore with an NPM of 38.0 per cent
Ipca Lab financial results – Below-par Q4 numbers but growth prospects intact: ICICI…
On the back of firm growth tempo in domestic formulations and good prospects both for API exports and formulation exports, we…
Abbott India Q4FY20 performance hit by COVID 19 impact: ICICI Securities
“We have reduced our revenue and EPS estimates for FY21E-FY22E by 4-5 per cent and 12-14 per cent to factor COVID-19 impact and…
Aurobindo’s Q4FY20 performance – Strong execution; net debt reduces further: ICICI…
The capital market firm raised Aurobindo Pharma's earnings estimates by 5-6 per cent to factor in higher revenue in US &…
Jubilant Life Sciences posts Rs 260.49 cr profit for Jan-Mar
Inspite of challenges, pharma biz segment growth likely to be healthy: ICICI Securities